Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a retroviral amphotropic envelope displaying single-chain variablefragment (scFv) directed against the c-Met receptor, to target the entry of recombinant retroviruses to human hepatocarcinoma cells. Four single-chain antibody fragments directed against the c-Met receptor were generated and inserted into the viral envelope protein as an N-terminal fusion. The modified envelopes were incorporated into virus particles and one of the chimeric viruses, 3D6-Env, transduced preferentially human hepatoma cells rather than proliferating human hepatocytes. In another construct, the urokinase cleavage site was inserted between the scFv moiety and the envelope. Chimeric scFv-urokinase-Env viruses transduced hepatoma cells with a similar efficiency to that of the control virus and their infectivity in human hepatocytes remained low. These results indicate that amphotropic retroviruses with engineered envelopes to display scFv directed against the c-Met receptor can efficiently and selectively deliver genes into hepatoma cells.
P rimary cancer of the liver is the sixth most common cancer in the world. Despite current therapies, the overall survival rate of patients with this disease remains very low. One of the most appealing concepts for tumor gene therapy is the transfer of genes encoding pro-drug activating enzymes, such as the thymidine kinase system, and/or genes that increase the cell death response. [1] [2] [3] A number of previous strategies used viral or ubiquitous promoters to drive the different genes. This meant that, depending on the gene transfer method used, uncontrolled gene expression might occur in multiple cell types. 4 To target more precisely the expression of toxic genes, it is desirable to identify and to use tissue-type-specific cellular transcriptional regulators such as a-lactalbumin in breast cancer or androgen-dependent prostate-specific gene. 5, 6 Thus, to restrict the expression to hepatoma cell types, specific sequences derived from insulin-like-growth factor 2 regulatory elements were inserted into adenoviral vectors to drive the expression of the thymidine kinase gene. 7 However, in this adenoviral context the IGFII promoter was constitutively activated. The alpha-fetoprotein (AFP) promoter was also used in adenoviral and retroviral vectors, but AFP transcripts were detected in noncancerous livers. [8] [9] [10] To date, no genes have been characterized, the expression of which is absolutely specific for hepatoma cells.
As selectivity and efficacy are critical for successful cancer gene therapy, targeting of tumor cells is required. However, the existing vectors all have a broad host range because their receptors are widely expressed. [11] [12] [13] Targeting of retroviruses may prevent both the delivery of toxic genes to dividing cells in the surrounding normal tissue and virus dissemination. It may also enhance the concentration of effective vectors in the target cells by localizing vectors at tumor sites.
The entry of retroviruses into cells is determined by the interaction of the virus surface (SU) envelope glycoprotein and a specific cell surface receptor. This interaction induces conformational changes in the associated transmembrane (TM) protein, promoting the fusion of the virus membrane with the cell membrane.
14 One of the strategies was to enhance the tropism of retrovirus to human target cells. Amphotropic envelopes were engineered based on the natural virus entry pathway via the interaction of the SU subunit to the Ram-1 receptor expressed on human cells. Different growth factors were displayed as N-terminal extension of the SU subunit. 15, 16 The chimeric viruses bound more tightly to human tumor cells, but this interaction resulted in the sequestration of virus particles onto the targeted receptors, which prevented subsequent binding of the SU subunit to Ram-1 and hence efficient gene transfer. However, the infectivity of chimeric virus particles targeting the EGF receptor could be restored by inserting a cleavage site for a matrixmetalloproteinase (MMP-2), a protease expressed on the cell-surface of the target tumor cells, between the growth factor domain and the SU subunit. In this two-step targeting strategy, the virus particles bound onto EGF receptors and the MMP-2 protease cleaved the EGF moiety from the SU subunit, thereby allowing it to bind to Ram-1 and virus entry. 17, 18 Amphotropic envelopes were also engineered to display a single-chain variablefragment (scFv) directed against different antigens. Interestingly, these chimeric viruses preferentially infected the target tumors cells at high titer. 19, 20 We recently demonstrated that retroviruses bearing hepatocyte growth factor/scatter (HGF) as a N-terminal extension of the envelope TM subunit, coexpressed with the amphotropic wild-type envelope, bind to the c-Met receptor and infect primary mouse and simian hepatocytes more efficiently than an unmodified virus. 21 This suggests the cooperative binding of the modified virus to c-Met via the HGF moiety and to Ram-1 via the SU subunit.
The c-met proto-oncogene, which encodes the HGF receptor, is overexpressed in a number of cancers including hepatocellular carcinoma. 21, 22 Numerous studies have shown that HGF/c-Met signalling increased the invasiveness and the metastatic potential of several carcinoma cell types and that the overexpression of cMet is correlated with a higher incidence of intrahepatic metastases . 23, 24 Urokinase-type plasminogen activator (uPA) belongs to a family of serine proteases involved in the degradation of the extracellular matrix and basement membrane. 25 Membrane-bound uPA is upregulated by HGF and uPA receptor expression is increased in various human tumor cells, including HCC cells. [26] [27] [28] To determine whether retroviral vectors with engineered envelopes can efficiently and specifically deliver genes into human HCC cells (HuH7, HepG2), we generated retroviruses bearing scFvs against two epitopes of c-Met, as a N-terminal extension of the SU subunit, and retroviruses in which a uPA cleavage site was inserted between the scFv moiety and the SU subunit. Our study shows that the viruses with engineered envelopes displaying a scfv against c-Met receptor infected efficiently HCC cells but poorly human primary hepatocytes in contrast to unmodified amphotropic retroviral vectors. We have also demonstrated that insertion of the cleavable uPA site in the chimeric envelope protein further increased the efficacy of engineered viruses toward HCC cells without impairing tumor cells selectivity.
Materials and methods

Cell lines
TELCeB6 cells were derived from human rhabdomyosarcoma. TELCeB6 cells stably produced MuLV gag-pol proteins and a packagable MFGnlsLacZ retroviral vector transcript. Therefore, they constitutively produced uninfectious retrovirus particles. FlyTA7 were derived from TELCeB6 and produced amphotropic retroviruses. 29 All cells were grown at 371C in an atmosphere of 5% CO 2 in Dulbecco-Vogt modified Eagle's medium (DMEM) (Eurobio, Les Ulis, France) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine and antibiotics (penicillin, streptomycin). NIH-3T3 cells were grown in DMEM with 10% heat-inactivated newborn calf serum. The human HCC cell lines, HuH7 and HepG2, were cultured in a mixture of 75% MEM and 25% Medium 199, supplemented with 10% FCS, antibiotics (penicillin, streptomycin), 5 mg/ml insulin, 1 mg/ml bovine serum albumin, and 7 Â 10 À7 M hydrocortisone hemisuccinate (Sigma Chemical Co.).
Primary human hepatocytes were isolated from biopsies of normal parenchyma obtained during partial hepatectomy from patients with benign hepatic tumors or metastatic tumors, after informed consent. The surgically removed fragment was perfused with collagenase A (Boehringer Mannheim Corp., Indianapolis, IN) by a two-step collagenase method as previously described. 30 The dissociated cells were suspended in hormonally defined medium (HDM): DMEM/HAMF-12 medium containing 1 Â 10 À8 M insulin, 10% (v/v) Myoclone Super Plus FCS (Gibco BRL, Cergy-Pontoise, France), 0.1% bovine serum albumin, 2 Â 10 À3 M glutamine and antibiotics. The cells were washed three times by centrifugation at 500 r.p.m. for 5 minutes and then suspended in HDM. Viability was checked by the trypan blue exclusion assay. They were seeded in the same HDM at a density of 2-5 Â 10 5 cells per 6-cm Primaria dish (Falcon, Becton-Dickinson); the medium was replaced 5 hours later and daily thereafter, by serum-free HDM: DMEM/HAMF-12 containing 1 Â 10
À3 M glutamine and antibiotics. TPA (1 Â 10 À7 M) was added to the culture medium 24 and 40 hours after plating. Recombinant HGF (20 ng/ml) (Genentech) was added to the culture medium 24, 40, 46, 48, 64 and 72 hours after plating.
Construction of retroviral vectors
5D5 and 3D6 scFvs were generated from cDNAs encoding the anti-human c-Met 5D5 and 3D6 antibodies. 31 . To construct these scFvs, the heavy-chain (V H ) 3 , GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGA TCG. To construct the chimeric envelope constructs, the scFvs DNA was digested with SfiI and NotI and inserted into an engineered envelope plasmid that had also been digested with SfiI and NotI. 32 The resulting plasmids, encoding an anti-c-Met scFvs fused to amphotropic SU 4070A residue +1, were named p5D5-Env and p3D6-Env. To construct the 3D6.uPA-Env envelope, a linker (GAT ATC AAA ACG AAA CAA TTG CGA GTT GTA AAT), flanked by NotI sticky ends, was inserted into p3D6-Env that had been digested with NotI.
Production and concentration of recombinant retroviruses. Modified envelope expression plasmids were transfected into TELCeB6 cells. The cells were cultured in medium containing 50 mg/ml phleomycin (Sigma, UK) for 14 days; resistant clones were pooled. Viruses were harvested from confluent cells incubated overnight in 2% FCS (5 ml), and filtered through filters with 0.45-mm pores. For some experiments, viral supernatants were concentrated to a titer of 1 Â 10 9 BCFU/ml (blue colonyforming units per milliliter) by tangential flow by use of a cartridge containing 40 kDa cutoff microfibers (Gambro Group, France). The cartridge was washed with 5 ml/minute saline for 20 minutes and with 5 ml/minute phosphate-buffered saline (PBS) for 10 minutes immediately before use. Refrigerated supernatant was circulated through the fibers at 10 ml/minute. The concentrated samples were immediately frozen and stored at À801C.
Western blots analysis
Viral and cellular proteins were isolated and analyzed as described previously. 32 . Briefly, cells were lyzed in L buffer (20 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.05% sodium dodecyl sulfate (SDS), 5 mg/ml sodium deoxycholate, 150 mM NaCl, and 1 mM phenylmethylsulfonyl fluoride) for 10 minutes at 41C. Lysates were clarified by centrifugation at 10,000 g for 10 minutes at 41C. Virus samples were obtained by ultracentrifugation of viral supernatants (15 ml) in a SW28 Beckman Rotor for 90 minutes at 25,000 rpm at 41C. Pellets were resuspended in 100 ml of PBS. Virus samples (10 ml) and cell extracts (30 mg) were subjected to SDS electrophoresis on 10% polyacrylamide gels. The proteins were transferred onto BA85 nitrocellulose membranes (Schleicher & Schuell). Filters were probed with goat antiserum directed against Rausher leukemia viral (RLV) gp70-SU envelope protein or RLV CAp30 capsid protein (Quality Biotech. Inc., Camden, NJ) and revealed with horseradish peroxidase (HRP)-conjugated rabbit anti-goat immunoglobulin antibodies (DAKO Ltd., UK) and the ECL Western blot Kit (Amersham, Little Chalfont, UK). Samples from hepatoma cells and primary human hepatocytes that had been cultured for 2 days, were incubated with a rabbit polyclonal antibody directed against human c-Met receptor or a goat polyclonal antibody directed against b-actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
To assess the cleavage by urokinase, 10 ml virus samples were incubated with 25 mU/ml urokinase protease (Hoechst, France) in PBS containing 0.01% Tween 20 for 90 minutes at 371C and then analyzed by Western blot, as described above.
Gene transfer assay. Retroviral vectors were titrated on NIH3T3. Cells (2 Â 10 5 ) were seeded into 6-cm dishes 24 hours before infection. Serial dilutions of the viral supernatant were made and the cells were overlaid with 1 ml medium containing 10 mg polybrene (Aldrich, WI) for 4 hours and then 3 ml of growth medium was added. After 48 hours of incubation, the cells were stained for bgalactosidase activity and titers (BCFU/ml) were calculated. 21 Infection efficiencies of wild-type and scFv-Env viruses on hepatoma cells or hepatocytes were obtained by infecting the cells with equal amounts of viral particles.
For infection experiments, hepatoma cells (5 Â 10 4 per six-well plate) were seeded 1 day before the experiment. The cells were incubated with 1 ml of viral supernatant containing 1 Â 10 7 BCFU and 10 mg polybrene for 4 hours. Primary human hepatocytes were infected 48 and 72 hours after plating with 1 ml of viral supernatant containing 1 Â 10 7 BCFU and 3 mg polybrene for 2 hours. Human hepatocytes were infected 46 and 70 hours after plating for 2 hours in the absence of HGF, by replacing culture medium with serum-free HDM containing 1 Â 10 7 infectious virus particles and 3 mg polybrene. Cells were then washed and infected cells were identified by X-Gal substrate staining 2 days later.
In c-Met saturation experiments, HuH7 were preincubated with increasing concentrations of 3D6 antibody (10 -500 mg/ml) for 30 minutes at 371C, prior to virus addition (1 ml of virus supernatant containing 1 Â 10 7 PFU as described above). For the inhibition of urokinase activity, 10 or 20 mM (final concentration) synthetic uPA-inhibitor B428 (kindly provided by Dr Littlefield) 33 was added to hepatoma cells at the time of infection and infection was carried out as above with serial dilutions of the viral supernatants. Results are expressed as relative infectivity and calculated formula follows: viral titer in the presence of uPA-inhibitor/viral titer in the absence of uPAinhibitor.
BrdU labelling index. To evaluate hepatocyte proliferation, bromodeoxyuridine (BrdU) (10 À5 M final) was added to the plates from days 1 to 3 after plating for a period of 16 hours. The plates were then washed and dried in an oven at 371C for 3-6 hours to fix the cells to the bottom of the plates. Cells were fixed with absolute ethanol for 10 minutes, air-dried, and denatured in formamide as previously described. 30 ) were then incubated with 1 ml of viral supernatant for 1 hour at 41C, washed twice in PBSFA and incubated with a c-Met-IgG fusion protein (35 mg/ml) for 1 hour at 41C. Cells were washed twice in PBSFA, and incubated with 1:100-diluted phycoerythrin-conjugated donkey anti-human Ig antibody (Jackson ImmunoResearch) in PBSFA for 1 hour at 41C. Nonviable cells were stained with 2 mg/ ml propidium iodide. The fluorescence of viable cells was then analyzed with a fluorescence-activated cell sorter (FACScan) (Becton Dickinson) by gating about 5 Â 10 3 cells. For these experiments, cell debris were eliminated from the analysis using a gate on forward and side scatters. Then viable cells were further gated according to propidium iodide fluorescence leading to about 2-3 Â 10 3 cells as described previously. 32 For specific competitive inhibition of binding, cells were incubated with 100 ng/ml of HGF and then with the virus. Immunofluorescence. For cell surface expression of urokinase, 1 Â 10 6 cells were detached in 2 mM EDTA, incubated with mouse monoclonal antibody directed against human urokinase (Santa Cruz Biotechnology Inc., Santa Cruz, CA), diluted 1:100 in PBSFA, for 1 hour at 41C, and then with anti-mouse fluorescein isothiocyanate (FITC)-conjugated antibody (DAKO Ltd, UK), before FACScan analysis (Becton Dickinson) as described for virus binding assays.
Results
Transduction of human hepatocytes and HCC cells by wild-type envelope recombinant retrovirus
To study the selectivity of amphotropic retroviral vectors, we defined optimal conditions for the efficient infection of human primary hepatocytes and HCC cells by use of recombinant control retroviruses expressing b-galactosidase. Human primary hepatocytes were stimulated to proliferate by the addition of HGF and BrdU incorporation was measured 24, 48 and 72 hours after plating. The labelling index is shown in Figure 1a . In our conditions, up to 50% of cultured hepatocytes divided within 2 days, 48 and 72 hours after plating. Hepatocarcinoma cells (HepG2 and HuH7) divided spontaneously. When seeded at a low density, 6575% and 6075% of HuH7 and HepG2 cells proliferated, respectively, 24 hours after plating (n ¼ 4).
Primary hepatocytes were then infected 46 and 70 h after plating at various multiplicities of infection (moi). At an moi of 10, all of the dividing cells (50% of hepatocytes) were transduced (Figure 1b) , which indicates that there is a good correlation between the number of proliferating hepatocytes and the transduction efficiency. Accordingly, in the absence of HGF stimulation no hepatocytes were transduced (not shown). At the time of HepG2 and HuH7 cells proliferation, up to 65% of the cells were transduced by the amphotropic retroviruses, showing that in our infection conditions, all dividing HCC cells were also transduced. As dividing cells represent the pool of cells susceptible to retroviral infection, these data indicate that wild-type-Env amphotropic viruses display no selectivity toward normal human hepatocytes or HCC cells. We assessed the viability of human primary hepatocytes after transduction by incubating the transduced cells with CFSE, which forms carboxyfluorescein in living cells. 
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More than 80% of human hepatocytes were viable after cell culture and transduction as shown by FACS analysis (Figure 1c ).
c-Met expression in hepatoma cells
The expression levels of c-Met in target cells, HuH7 cells and dividing human primary hepatocytes, were determined by Western blot analysis. In human hepatocytes, the processed b-subunit (145 kDa) and a 190 kDa precursor form were detected. In hepatoma cells, the anti-c-Met antiserum detected a precursor form (170 kDa) and the Met b-subunit (145 kDa) (Figure 2a) , which was expressed at slightly higher level (1.6-fold) than in proliferating primary hepatocytes, as shown by the bsubunit c-Met-to-b-actin ratios (Figure 2b) . No specific bands were detected in TELCeB6 cell extracts.
Generation of chimeric vectors
Two scFvs (3D6, 5D5) were generated by PCR from the cDNA of monoclonal antibodies directed against the human c-Met receptor, which have a similar binding affinity for c-Met (data not shown). These anti-Met scFvs were inserted between the signal peptide and the amino acid at position +1 of the amphotropic SU envelope glycoprotein. This generated chimeric scFv envelope glycoproteins (Figure 3 ). Another chimeric envelope was produced in which a cleavable linker containing the urokinase (uPA) recognition site was inserted after the 3D6 scFv moiety (3D6.uPA-Env). The uPA cleavage site corresponds to the sequence flanking the pro-HGF cleavage site (Figure 3 ). Pro-HGF is cleaved between the Arg 494 -Val 495 in this sequence by urokinase to yield the mature active two-chain HGF. 34 The chimeric envelope expression plasmids (3D6 and 5D5) were transfected into TELCeB6 cells and stably transfected cells were pooled for further analysis.
Incorporation of chimeric envelopes into virions and specificity of virus binding to c-Met
Virions from bulk populations of producer cells were collected and tested for chimeric envelopes by Western blotting using a polyclonal viral SU antibody (80 kDa) (Figure 4a, lane TA7) . The incorporation of the chimeric envelope into virions was remarkably efficient (Figure 4a) . Consistent with the size of the scFv (approximately 30 kDa), the chimeric envelopes had the predicted size of 110 kDa for processed SU. The amount of chimeric envelopes incorporated was approximately half that of the wild-type amphotropic envelopes, as assessed by Envto-p30 CA ratios. Viruses harvested from untransfected TELCeB6 cells gave no signals. We investigated whether exogenous urokinase recognized the cleavage sequence on the 3D6.uPA-Env viruses and cleaved the scFv domain from the chimeric viral envelope by incubating 3D6.uPAEnv and unmodified envelope virus pellets with urokinase and carrying out immunoblotting as before. Treatment of 3D6.uPA-Env with urokinase gave a band of similar mobility to the wild-type SU, indicating that the scFv domain could be cleaved from the chimeric envelope (Figure 4b) , although not completely.
We assessed the binding of the chimeric envelope to the c-Met receptor via the scFv moiety by incubating HuH7 cells with viral supernatants, as previously described. 32 Virus binding was detected by FACS using a soluble cMet receptor, a fusion protein between the extracellular domain of c-Met and a constant domain of mouse IgG1. 29 The c-Met extracellular domain can bind to chimeric viruses via the scFv moiety and this binding is detected using a secondary antibody directed against mouse IgG1. The chimeric envelope bound to HuH7 cells (Figure 4c ). This binding was competitively inhibited by recombinant HGF, demonstrating that the scFv-envelope specifically binds to the c-Met receptor. As expected, no significant binding was detected with the wild-type amphotropic envelope. 
Viral infection of human primary hepatocytes and hepatoma cells
Titration experiments were carried out on NIH3T3 cells, which do not express c-Met receptor. The titer of the control amphotropic virus (TA7) was 1 Â 10 8 BCFU/ml. The titer of the 5D5-Env and 3D6-Env virus was 1 Â 10 7 and to 5 Â 10 7 BCFU/ml respectively. The titer of the 3D6.uPA-Env virus was 5 Â 10 7 BCFU/ml. We conclude therefore that the modified envelopes are not impaired in their ability to bind the natural virus receptor (Ram-1) and to allow subsequent virus entry.
We then investigated chimeric virus infectivity on HCC cells and hepatocytes. For these experiments, we added an equal amount of virus particles, as estimated by titration on NIH3T3 cells. Viruses displaying 5D5 scFv poorly infected both cell types. In contrast, the 3D6-Env virus retained good infectivity on hepatoma cells (10-18%). When these chimeric viruses were concentrated and 10-fold higher amount of virus particles was added on HuH7 cells, the transduction efficiency increased to 60%, reaching almost the transduction efficiency of the wildtype envelope viruses (70%), whereas it remained severely impaired on primary hepatocytes (1%) (Figure 5a,b) . As a control, human hepatocytes were reproducibly and highly transduced by wild-type Env virus (40-50%). This inability to readily infect human hepatocytes was also observed with monkey hepatocytes; 1% of these cells were infected with the 3D6-Env virus, whereas up to 90% of these cells were infected with the wild-type envelope virus. 35 To determine whether the partial inhibition of the 3D6-Env virus observed on c-Met-expressing cells was due to its binding to the c-Met receptor, HuH7 were preincubated with increasing amounts of 3D6 antibodies to saturate c-Met before infection. This resulted in increased infectivity, which was correlated to the amount of 3D6 antibodies added onto the cells (Figure 5c ). The transduction efficiency increased from 10 to 50% on HuH7 cells, whereas that of wild-type-Env virus remained unchanged.
Infectivity of 3D6.uPA-Env viruses
FACS analysis was then used to evaluate the expression of urokinase in hepatoma cells. Urokinase was expressed by all HuH7 cells, but not by TELCeB6 cells, which were used as a negative control (Figure 6a) . HuH7 cells were then infected with unconcentrated 3D6.uPA-Env virus and up to 50% of the cells were transduced (Figure 6b) . Viability of human primary hepatocytes after transduction with chimeric Env virus was as high as for wild-type Env virus (Figure 6d ). When cell infection experiments were carried out in the presence of 10 or 20 mM uPA-inhibitor, 3D6.uPA-Env viral infectivity was decreased by 1.6-and 2.5-fold, respectively (Figure 6c ). These data indicate that the increased infectivity of 3D6.uPA-Env on human hepatoma cells was due to endogenous secreted urokinase. The infectivity of wildtype Env virus was not affected by the uPA-inhibitor. In contrast, human hepatocytes were still poorly infected (o1%) (Figure 6b) , which is consistent with their lack of urokinase production.
Discussion
One of the challenges in the engineering of amphotropic retroviral envelope proteins is to direct specific viruses to cell-surface molecules expressed by tumor cells, without impairing viral entry. Up to now, no report has shown efficient and preferential infection of HCC cells with amphotropic retroviral vectors. In this work, we show that amphotropic viruses targeted to c-Met receptors via 3D6 scFv exhibited a high rate of infectivity and were selective for human hepatic tumor cells compared to their normal primary counterparts. We also observed a partial sequestration upon binding of 3D6 scFv-virus to c-Met. Infection experiments in the presence of 3D6 antibody suggest that this binding partially impairs the binding of SU to Ram-1, probably due to steric hindrance. However, this impaired infectivity on HCC cells was overcome when higher amount of 3D6 scFv-virus particles was used for cell infection. In contrast, the transduction rate remained low for human hepatocytes.
The viruses displaying 5D5 scFv, which recognizes another c-Met epitope, were impaired in their ability to infect c-Met-positive cells although they infected c-Metnegative cells at high titer. These results support previous reports showing that binding of the engineered envelope to targeted receptors can sequester and prevent the binding of SU subunit to its natural viral receptor Ram-1. 15, 16, 32 These results also show that the engineered viruses could not use the c-Met receptors as a surrogate receptor for virus entry. As both 5D5 and 3D6 scFvs have similar binding affinities for the c-Met receptor, epitope specificity and/or scFv structure is probably critical for virus entry. Thus, in addition to the choice of the targeted cell-surface proteins, 15, 16, 19, 20 our results show that that different ligands for a same receptor are not equivalent for retrovirus targeting. The choice of ligand for engineering the virus envelope is critical for the success of gene delivery.
A two-step strategy to deliver protease-activated gene vectors was previously successfully used by Peng et al 17, 18 to deliver genes selectively to cells producing matrix metalloproteinases. Urokinase is one of the proteases secreted by hepatocarcinoma cells. 27 Thus, we postulated that the targeted vector containing a uPA cleavable site in the engineered envelope can be activated by endogenous urokinase. Indeed, the infectivity of these 3D6.uPA-Env viruses was increased by cleaving the uPAsensitive linker with endogenous membrane-associated urokinase on HCC cells compared to infectivity of 3D6-env viruses, as more than 50% of HCC cells were transduced without virus concentration. Cleavage of the scFv moiety enabled the virus to dissociate from c-Met and restored the ability of the SU to attach to its receptor. Human hepatocytes do not produce urokinase 23 and accordingly the infectivity of 3D6.uPA-Env remained low on these cells. This also shows that entry of 3D6-uPA Env virus particles does not occur through the targeted c-Met receptor but, as for wild-type virus, through SU:Ram-1 binding.
Different hypotheses might explain the selective infection of HCC cells by chimeric viruses. Interactions between HGF and c-Met receptors promote pleiotropic biological responses including cell division, cell motility, extracellular invasion, survival and morphogenic differentiation depending on the cell type. Prat et al. 36 showed that two scFvs directed against c-Met elicited different biological activities upon binding to c-Met. Other reports suggest that different allosteric conformations may elicit the pleiotropic biological activities of c-Met. 37 Our results with 5D5-Env and 3D6-Env viruses could be an another example of different c-Met allosteric conformations and/ or accessibility. A difference between HCC cells and primary hepatocytes is that proliferation of primary hepatocytes is dependent on c-Met signalling (via HGF), whereas HCC cells spontaneously proliferate, suggesting that the routing and signalling of c-Met upon binding to HGF is different in the two cell systems. Therefore, the selectivity of the chimeric viruses for HCC cells might be due to a conformational state of c-Met sequestering chimeric viruses more tightly onto human primary hepatocytes than onto HCC cells. Also, an abnormal subcellular distribution of c-Met in adenocarcinomas of the pancreas with respect to normal pancreatic cells was described. 38 Thus, the different susceptibility of HCC cells and primary hepatocytes to chimeric viruses may be also related to an abnormal cellsurface distribution or clustering of the c-Met receptor in HCC cells.
It is noteworthy that all previous studies have evaluated selectivity of chimeric envelope viruses using established cell lines expressing or not the targeted receptor, and none has used primary culture of normal counterpart cells.
We expect that the selectivity of 3D6.uPA-Env vectors in vitro should also occur in vivo in human hepatocarcinomas : (i) in vivo data indicate that the c-Met receptor is overproduced in human HCC and is not expressed in normal human livers. 22, 39 The c-Met targeted viruses should be preferentially sequestrated in hepatic tumor sites after systemic delivery, therefore limiting virus dissemination. Indeed, recent studies showed that matrix-targeted amphotropic retroviral vectors accumulated preferentially in tumor sites after systemic delivery even though they could still bind to the widespread expressed Ram-1 receptor. 20 (ii) As dividing normal hepatocytes are not transduced by the chimeric viruses, they should not be toxic to nontumorous liver cells, adjacent and distant to the tumor sites. (iii) Previous studies have shown that all of the HCCs studied and none of the nontumorous liver cells expressed the uPA and uPA receptors. 40 This would ensure the selectivity of the protease two-step strategy for the 3D6-uPA.Env virus.
In conclusion, our study has demonstrated that amphotropic viruses targeted to the c-Met receptor are infective and selective for human hepatic tumor cells and that the two-step strategy is efficient in this model. Insertion of a uPA-activable linker in the engineered envelope are critical for the efficacy of infection of HCC cells. Such vectors could be expected to be a useful strategy, based on nonreplicative or replicative retrovirus 41, 42 to deliver toxic genes into HCCs.
